1. Academic Validation
  2. Design and Synthesis of Bitopic 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as Selective Dopamine D3 Receptor Ligands

Design and Synthesis of Bitopic 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as Selective Dopamine D3 Receptor Ligands

  • J Med Chem. 2020 May 14;63(9):4579-4602. doi: 10.1021/acs.jmedchem.9b01835.
Liang Tan 1 Qingtong Zhou 1 Wenzhong Yan 1 Jian Sun 1 Alan P Kozikowski 2 Suwen Zhao 1 3 Xi-Ping Huang 4 Jianjun Cheng 1
Affiliations

Affiliations

  • 1 iHuman Institute, ShanghaiTech University, 393 Middle Huaxia Road, Pudong New District, Shanghai 201210, China.
  • 2 StarWise Therapeutics LLC, 2020 North Lincoln Park West, Chicago Illinois 60614, United States.
  • 3 School of Life Science and Technology, ShanghaiTech University, 393 Middle Huaxia Road, Pudong New District, Shanghai 201210, China.
  • 4 Department of Pharmacology, National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP), University of North Carolina Chapel Hill Medical School, Chapel Hill, North Carolina 27599, United States.
Abstract

2-Phenylcyclopropylmethylamine (PCPMA) analogues have been reported as selective serotonin 2C agonists. On the basis of the same scaffold, we designed and synthesized a series of bitopic derivatives as dopamine D3R ligands. A number of these new compounds show a high binding affinity for D3R with excellent selectivity. Compound (1R,2R)-22e and its enantiomer (1S,2S)-22e show a comparable binding affinity for the D3R, but the former is a potent D3R agonist, while the latter acts as an antagonist. Molecular docking studies revealed different binding poses of the PCPMA moiety within the orthosteric binding pocket of the D3R, which might explain the different functional profiles of the enantiomers. Compound (1R,2R)-30q shows a high binding affinity for the D3R (Ki = 2.2 nM) along with good selectivity, as well as good bioavailability and brain penetration properties in mice. These results reveal that the PCPMA scaffold may serve as a privileged scaffold for the design of aminergic GPCR ligands.

Figures